Novo Integrated Sciences today announced the signing of non-binding Letters of Intent to acquire seven pharmacies in the United States. The proposed all-stock transactions contemplate the acquisition of a 50% interest in each pharmacy. Novo expects to negotiate and enter into definitive agreements and to close the acquisitions before the end of the year.
The seven pharmacies collectively generated approximately $55 million in annualized revenue in 2020, Novo said n a press release. The acquisitions would establish the company’s footprint in Florida, Virginia, and Arizona. Read more.
